Literature DB >> 1551632

The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis.

N Bach1, S N Thung, F Schaffner.   

Abstract

Before the availability of serological markers for hepatitis C, the morphological features of this diagnosis, which represents most non-A, non-B hepatitis, could not be confirmed. We examined biopsy specimens from 50 patients with chronic hepatitis C and 21 patients with autoimmune chronic hepatitis. Each biopsy specimen was graded on 19 different histological features. The results indicated that at the time of biopsy, the average age of patients with chronic hepatitis C was 46 yr vs. 36 yr for autoimmune chronic hepatitis. Cirrhosis was seen more frequently in autoimmune chronic hepatitis (90%) than in hepatitis C (58%). Features more commonly observed in chronic hepatitis C were bile duct damage (91% vs. 40%), bile duct loss (91% vs. 20%), steatosis (72% vs. 19%) and lymphoid cell aggregation (follicles) within portal tracts (49% vs. 10%). Severe lobular necrosis and inflammation (76% vs. 38%), piecemeal necrosis (81% vs. 10%), multinucleated hepatocytes (29% vs. 6%) and broad areas of parenchymal collapse (76% vs. 6%) were seen more often in autoimmune chronic hepatitis. Exclusion of five patients with autoimmune chronic hepatitis who received immunosuppression before biopsy accentuated these differences. In conclusion, morphological criteria, in addition to serological data, may be useful for differentiating chronic hepatitis C from autoimmune chronic hepatitis, which histologically is a more aggressive disease.

Entities:  

Mesh:

Year:  1992        PMID: 1551632     DOI: 10.1002/hep.1840150403

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  85 in total

Review 1.  Autoimmune hepatitis and its variant syndromes.

Authors:  Z Ben-Ari; A J Czaja
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

2.  Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.

Authors:  A B Jazwinski; A J Thompson; P J Clark; S Naggie; H L Tillmann; K Patel
Journal:  J Viral Hepat       Date:  2011-11-24       Impact factor: 3.728

3.  A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome.

Authors:  Rabin Rahmani; Thomas D Schiano
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-04

4.  A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome.

Authors:  Ashaur Azhar; Mumtaz A Niazi; Kashif Tufail; Ashraf H Malek; Manjula Balasubramanian; Victor Araya
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-04

Review 5.  Hepatitis C as a systemic disease: virus and host immunologic responses underlie hepatic and extrahepatic manifestations.

Authors:  Chiaki Okuse; Hiroshi Yotsuyanagi; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2007-11-22       Impact factor: 7.527

Review 6.  Hepatitis C: diagnosis and treatment.

Authors:  I Scotiniotis; C A Brass; P F Malet
Journal:  J Gen Intern Med       Date:  1995-05       Impact factor: 5.128

7.  MicroRNA-185-5p mediates regulation of SREBP2 expression by hepatitis C virus core protein.

Authors:  Min Li; Qi Wang; Shun-Ai Liu; Jin-Qian Zhang; Wei Ju; Min Quan; Sheng-Hu Feng; Jin-Ling Dong; Ping Gao; Jun Cheng
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

8.  Chronic hepatitis in experimental schistosomiasis.

Authors:  Z A Andrade; A W Cheever
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

9.  Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection.

Authors:  Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2009-01-16       Impact factor: 7.527

10.  In vivo, high-field, 3-Tesla 1H MR spectroscopic assessment of liver fibrosis in HCV-correlated chronic liver disease.

Authors:  A Orlacchio; F Bolacchi; M Angelico; A Mancini; V Cozzolino; M Cadioli; G Simonetti
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.